Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559674 · ClinicalTrials.gov registry record · Phase 1
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
A Phase 1 study, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02559674: Completed Phase 1 study, sponsored by Altor BioScience.
NCT02559674 is a Phase 1 study that has completed, run by Altor BioScience. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02559674, a Phase 1 study, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose escalation study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer in conjunction with gemcitabine and nab-paclitaxel.
Primary Outcome
Determine the maximum tolerated dose (MTD) level and designate the recommended dose level for phase II.
Interventions
- BIOLOGICAL Gemcitabine
- BIOLOGICAL ALT-803
- BIOLOGICAL Nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-02-21 |
| Phase | Phase 1 |
What the finished NCT02559674 record still lists
NCT02559674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02559674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02559674 about?
NCT02559674 is a clinical study titled "QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel". This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose escalation study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer in conjunction with gemcitabine and nab-paclitaxel.
What is the current status of trial NCT02559674?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-07. Estimated completion is 2018-02-21.
What interventions are being tested in trial NCT02559674?
The interventions under investigation include: Gemcitabine (BIOLOGICAL), ALT-803 (BIOLOGICAL), Nab-paclitaxel (BIOLOGICAL).
Who is sponsoring clinical trial NCT02559674?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02559674's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia